Sarepta Therapeutics, Inc. (LON:0L35)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.84B |
| Revenue (ttm) | 1.73B |
| Net Income (ttm) | -192.25M |
| Shares Out | n/a |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | 6.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,279 |
| Average Volume | 9,561 |
| Open | 38.33 |
| Previous Close | 37.19 |
| Day's Range | 37.20 - 39.12 |
| 52-Week Range | 34.23 - 175.10 |
| Beta | 0.84 |
| RSI | 33.26 |
| Earnings Date | May 5, 2025 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
News
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as E...
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data from Part 2 of the EMBARK study that c...
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, a...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors ar...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are ...
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
SA analyst downgrades: BTI, HSY, SRPT, HIMS, S
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investor...
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a Hold.
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Sarepta Therapeutics Inc . (NASDAQ: SRPT) reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents . Quarterly revenue ...
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Sarepta Therapeutics Stock Plunges on Guidance Cut. Its Moneymaker Is Under Fire.
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) posted a loss for the first quarter on Tuesday . Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estima...
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
Sarepta Therapeutics, Inc. SRPT posted a loss for the first quarter on Tuesday.
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday. Shares of Sarepta Therapeutics, Inc . (NASDAQ: SRPT) fell sharply in today's pre-market trading...
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsMary Jenkins - Associate Director,...
Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares are sinking after the company released its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report. The Detai...
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million...
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. “I...
Sarepta Therapeutics Q1 2025 Earnings Preview
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are ...